132 related articles for article (PubMed ID: 38801321)
1. Identification of isoaspartate-modified transthyretin as potential target for selective immunotherapy of transthyretin amyloidosis.
Köppen J; Kleinschmidt M; Morawski M; Rahfeld JU; Wermann M; Cynis H; Hegenbart U; Daniel C; Roßner S; Schilling S; Schulze A
Amyloid; 2024 May; ():1-11. PubMed ID: 38801321
[TBL] [Abstract][Full Text] [Related]
2. Novel conformation-specific monoclonal antibodies against amyloidogenic forms of transthyretin.
Higaki JN; Chakrabartty A; Galant NJ; Hadley KC; Hammerson B; Nijjar T; Torres R; Tapia JR; Salmans J; Barbour R; Tam SJ; Flanagan K; Zago W; Kinney GG
Amyloid; 2016 Jun; 23(2):86-97. PubMed ID: 26981744
[TBL] [Abstract][Full Text] [Related]
3. Novel Antibody for the Treatment of Transthyretin Amyloidosis.
Hosoi A; Su Y; Torikai M; Jono H; Ishikawa D; Soejima K; Higuchi H; Guo J; Ueda M; Suenaga G; Motokawa H; Ikeda T; Senju S; Nakashima T; Ando Y
J Biol Chem; 2016 Nov; 291(48):25096-25105. PubMed ID: 27758856
[TBL] [Abstract][Full Text] [Related]
4. Transthyretin aggregate-specific antibodies recognize cryptic epitopes on patient-derived amyloid fibrils.
Phay M; Blinder V; Macy S; Greene MJ; Wooliver DC; Liu W; Planas A; Walsh DM; Connors LH; Primmer SR; Planque SA; Paul S; O'Nuallain B
Rejuvenation Res; 2014 Apr; 17(2):97-104. PubMed ID: 24164623
[TBL] [Abstract][Full Text] [Related]
5. Transthyretin fibrillogenesis entails the assembly of monomers: a molecular model for in vitro assembled transthyretin amyloid-like fibrils.
Cardoso I; Goldsbury CS; Müller SA; Olivieri V; Wirtz S; Damas AM; Aebi U; Saraiva MJ
J Mol Biol; 2002 Apr; 317(5):683-95. PubMed ID: 11955017
[TBL] [Abstract][Full Text] [Related]
6. Targeting isoaspartate-modified Aβ rescues behavioral deficits in transgenic mice with Alzheimer's disease-like pathology.
Gnoth K; Piechotta A; Kleinschmidt M; Konrath S; Schenk M; Taudte N; Ramsbeck D; Rieckmann V; Geissler S; Eichentopf R; Barendrecht S; Hartlage-Rübsamen M; Demuth HU; Roßner S; Cynis H; Rahfeld JU; Schilling S
Alzheimers Res Ther; 2020 Nov; 12(1):149. PubMed ID: 33189132
[TBL] [Abstract][Full Text] [Related]
7. Selective recognition of human small transthyretin aggregates by a novel monoclonal antibody.
Teixeira AC; Saraiva MJ
Amyloid; 2023 Mar; 30(1):74-80. PubMed ID: 36111397
[TBL] [Abstract][Full Text] [Related]
8. Amyloid and nonfibrillar deposits in mice transgenic for wild-type human transthyretin: a possible model for senile systemic amyloidosis.
Teng MH; Yin JY; Vidal R; Ghiso J; Kumar A; Rabenou R; Shah A; Jacobson DR; Tagoe C; Gallo G; Buxbaum J
Lab Invest; 2001 Mar; 81(3):385-96. PubMed ID: 11310831
[TBL] [Abstract][Full Text] [Related]
9. Inhibitors of Transthyretin Amyloidosis: How to Rank Drug Candidates Using X-ray Crystallography Data.
Leite JP; Costa-Rodrigues D; Gales L
Molecules; 2024 Feb; 29(4):. PubMed ID: 38398647
[TBL] [Abstract][Full Text] [Related]
10. 4'-Iodo-4'-deoxydoxorubicin disrupts the fibrillar structure of transthyretin amyloid.
Palha JA; Ballinari D; Amboldi N; Cardoso I; Fernandes R; Bellotti V; Merlini G; Saraiva MJ
Am J Pathol; 2000 Jun; 156(6):1919-25. PubMed ID: 10854215
[TBL] [Abstract][Full Text] [Related]
11. Extracellular Vesicles Contribute to the Metabolism of Transthyretin Amyloid in Hereditary Transthyretin Amyloidosis.
Yamaguchi H; Kawahara H; Kodera N; Kumaki A; Tada Y; Tang Z; Sakai K; Ono K; Yamada M; Hanayama R
Front Mol Biosci; 2022; 9():839917. PubMed ID: 35402512
[TBL] [Abstract][Full Text] [Related]
12. Characteristics of Patients with Hereditary Transthyretin Amyloidosis-Polyneuropathy (ATTRv-PN) in NEURO-TTRansform, an Open-label Phase 3 Study of Eplontersen.
Coelho T; Waddington Cruz M; Chao CC; Parman Y; Wixner J; Weiler M; Barroso FA; Dasgupta NR; Jung SW; Schneider E; Viney NJ; Dyck PJB; Ando Y; Gillmore JD; Khella S; Gertz MA; Obici L; Berk JL
Neurol Ther; 2023 Feb; 12(1):267-287. PubMed ID: 36525140
[TBL] [Abstract][Full Text] [Related]
13. Cutaneous lymphatic amyloid deposits in "Hungarian-type" familial transthyretin amyloidosis: a case report.
Harkany T; Garzuly F; Csanaky G; Luiten PG; Nyakas C; Linke RP; Virágh S
Br J Dermatol; 2002 Apr; 146(4):674-9. PubMed ID: 11966704
[TBL] [Abstract][Full Text] [Related]
14. Substoichiometric inhibition of transthyretin misfolding by immune-targeting sparsely populated misfolding intermediates: a potential diagnostic and therapeutic for TTR amyloidoses.
Galant NJ; Bugyei-Twum A; Rakhit R; Walsh P; Sharpe S; Arslan PE; Westermark P; Higaki JN; Torres R; Tapia J; Chakrabartty A
Sci Rep; 2016 Apr; 6():25080. PubMed ID: 27122057
[TBL] [Abstract][Full Text] [Related]
15. Mechanisms of transthyretin amyloidogenesis. Antigenic mapping of transthyretin purified from plasma and amyloid fibrils and within in situ tissue localizations.
Gustavsson A; Engström U; Westermark P
Am J Pathol; 1994 Jun; 144(6):1301-11. PubMed ID: 8203468
[TBL] [Abstract][Full Text] [Related]
16. Transthyretin amyloid fibrils alter primary fibroblast structure, function, and inflammatory gene expression.
Dittloff KT; Iezzi A; Zhong JX; Mohindra P; Desai TA; Russell B
Am J Physiol Heart Circ Physiol; 2021 Jul; 321(1):H149-H160. PubMed ID: 34018852
[TBL] [Abstract][Full Text] [Related]
17. Transthyretin Anti-Amyloidogenic and Fibril Disrupting Activities of
Eze FN; Ingkaninan K; Prapunpoj P
Biomolecules; 2019 Dec; 9(12):. PubMed ID: 31835306
[TBL] [Abstract][Full Text] [Related]
18. Transthyretin Stabilizers and Seeding Inhibitors as Therapies for Amyloid Transthyretin Cardiomyopathy.
Morfino P; Aimo A; Vergaro G; Sanguinetti C; Castiglione V; Franzini M; Perrone MA; Emdin M
Pharmaceutics; 2023 Apr; 15(4):. PubMed ID: 37111614
[TBL] [Abstract][Full Text] [Related]
19. A novel monoclonal antibody targeting aggregated transthyretin facilitates its removal and functional recovery in an experimental model.
George J; Rappaport M; Shimoni S; Goland S; Voldarsky I; Fabricant Y; Edri O; Cuciuc V; Lifshitz S; Tshori S; Fassler M
Eur Heart J; 2020 Mar; 41(12):1260-1270. PubMed ID: 31865366
[TBL] [Abstract][Full Text] [Related]
20. Identification of a novel transthyretin mutation D39Y in a cardiac amyloidosis patient and its biochemical characterizations.
Ma Q; Wang M; Huang Y; Nie Y; Zhang X; Yang DD; Wang Z; Ding S; Qian N; Liu Y; Pan X
Front Cardiovasc Med; 2023; 10():1091183. PubMed ID: 36776255
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
